glp-1 agonist and dpp-4 inhibitor Receptor Agonists Dipeptidyl peptidase-4 inhibitor treatment induces

The CagriSema protocol shows the combined possible of combining amylin and GLP-1 pathways

The time for which the effects of Q-Car Tablet last: The duration of action for Q-Car Tablet is clinically unknown

Think of it like this

A1C reduction comparison A network meta-analysis published in BMC Endocrine Disorders in 2024, analyzing 26 clinical studies, found the following A1C reductions compared to placebo: Tirzepatide 15mg: -2.24% A1C reduction Tirzepatide 10mg: -1.99% A1C reduction Tirzepatide 5mg: -1.82% A1C reduction Liraglutide 1.8mg: approximately -1.3% A1C reduction Liraglutide 1.2mg: -1.23% A1C reduction At the highest respective doses, tirzepatide reduces A1C by nearly twice as much as liraglutide